TY - JOUR
T1 - Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy
AU - Gill, Suki
AU - Li, J.
AU - Thomas, J.
AU - Bressel, Mathias
AU - Thursky, Karin A
AU - Styles, Colin B
AU - Tai, K. H.
AU - Duchesne, G M
AU - Foroudi, Farshad
PY - 2012/7
Y1 - 2012/7
N2 - Objectives: To report on complications from transrectal ultrasound-guided insertion of fiducial markers for prostate image-guided radiotherapy. Methods: 234 patients who underwent transrectal fiducial marker insertion for prostate cancer image-guided radiotherapy were assessed retrospectively by questionnaire with regard to the duration and severity of eight symptoms experienced following the procedure. Pain during the implantation procedure was assessed according to the Wong-Baker faces pain scale. Results: Of 234 patients, 32% had at least one new symptom after the procedure. The commonest new symptom following the procedure was urinary frequency affecting 16% of patients who had not been troubled by frequency beforehand. Haematuria, rectal bleeding, dysuria and haematospermia affected 9-13% of patients, mostly at Grade 1 or 2. Pain, obstruction, and fever and shivers affected 3-4% of patients. Grade 3 rectal bleeding, haematuria, fever and shivers, and urinary frequency affected 0.5-1.5% of patients. Only one patient had a Grade 4 complication (i.e. fever and shivers). Overall, 9% of patients had symptoms lasting more than 2 weeks. The commonest symptoms that lasted more than 2 weeks were frequency, dysuria, obstructive symptoms and rectal bleeding. Mean pain score during the procedure was 1.1 (range 0-5). Conclusion: Transrectal ultrasound-guided fiducial marker insertion for image-guided radiotherapy is well tolerated in the majority of prostate cancer patients. Most symptoms were Grade 1 or 2 in severity. Symptoms in the majority of patients last under 2 weeks. The most serious complication was sepsis in our study.
AB - Objectives: To report on complications from transrectal ultrasound-guided insertion of fiducial markers for prostate image-guided radiotherapy. Methods: 234 patients who underwent transrectal fiducial marker insertion for prostate cancer image-guided radiotherapy were assessed retrospectively by questionnaire with regard to the duration and severity of eight symptoms experienced following the procedure. Pain during the implantation procedure was assessed according to the Wong-Baker faces pain scale. Results: Of 234 patients, 32% had at least one new symptom after the procedure. The commonest new symptom following the procedure was urinary frequency affecting 16% of patients who had not been troubled by frequency beforehand. Haematuria, rectal bleeding, dysuria and haematospermia affected 9-13% of patients, mostly at Grade 1 or 2. Pain, obstruction, and fever and shivers affected 3-4% of patients. Grade 3 rectal bleeding, haematuria, fever and shivers, and urinary frequency affected 0.5-1.5% of patients. Only one patient had a Grade 4 complication (i.e. fever and shivers). Overall, 9% of patients had symptoms lasting more than 2 weeks. The commonest symptoms that lasted more than 2 weeks were frequency, dysuria, obstructive symptoms and rectal bleeding. Mean pain score during the procedure was 1.1 (range 0-5). Conclusion: Transrectal ultrasound-guided fiducial marker insertion for image-guided radiotherapy is well tolerated in the majority of prostate cancer patients. Most symptoms were Grade 1 or 2 in severity. Symptoms in the majority of patients last under 2 weeks. The most serious complication was sepsis in our study.
UR - http://www.scopus.com/inward/record.url?scp=84863651613&partnerID=8YFLogxK
U2 - 10.1259/bjr/68127917
DO - 10.1259/bjr/68127917
M3 - Article
C2 - 22253345
AN - SCOPUS:84863651613
VL - 85
SP - 1011
EP - 1017
JO - British Journal of Radiology
JF - British Journal of Radiology
SN - 0007-1285
IS - 1015
ER -